Luca Richeldi mainly focuses on Idiopathic pulmonary fibrosis, Internal medicine, Immunology, Nintedanib and Intensive care medicine. His Idiopathic pulmonary fibrosis study combines topics from a wide range of disciplines, such as Physical therapy, Surgery, FEV1/FVC ratio and Interstitial lung disease. His study in Interstitial lung disease is interdisciplinary in nature, drawing from both Guideline, Pathology and Lung biopsy.
His work in Internal medicine addresses issues such as Placebo, which are connected to fields such as Gastroenterology and Quality of life. Luca Richeldi interconnects Beryllium Disease, Chemotherapy, Tuberculosis and Berylliosis in the investigation of issues within Immunology. His Intensive care medicine research is multidisciplinary, incorporating elements of International working group, Idiopathic interstitial pneumonia, Evidence-based practice, Disease and Combined pulmonary fibrosis and emphysema.
Idiopathic pulmonary fibrosis, Internal medicine, Nintedanib, Intensive care medicine and Interstitial lung disease are his primary areas of study. In Idiopathic pulmonary fibrosis, he works on issues like Pathology, which are connected to Lung. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Placebo.
Luca Richeldi combines subjects such as Disease progression, Oncology, Cardiology and Tolerability, Adverse effect with his study of Nintedanib. His study looks at the relationship between Intensive care medicine and fields such as Disease, as well as how they intersect with chemical problems. His study of Usual interstitial pneumonia is a part of Interstitial lung disease.
Luca Richeldi focuses on Internal medicine, Idiopathic pulmonary fibrosis, Nintedanib, Interstitial lung disease and Lung. His research brings together the fields of Gastroenterology and Internal medicine. The various areas that Luca Richeldi examines in his Idiopathic pulmonary fibrosis study include Clinical trial, Tolerability, FEV1/FVC ratio, Intensive care medicine and Fibrosis.
His FEV1/FVC ratio research focuses on Placebo and how it connects with Exacerbation. His Nintedanib research integrates issues from Pirfenidone and Oncology. Luca Richeldi has included themes like Disease progression, Hypersensitivity pneumonitis and Pathology in his Interstitial lung disease study.
His primary scientific interests are in Idiopathic pulmonary fibrosis, Internal medicine, Coronavirus disease 2019, Pandemic and Intensive care medicine. His study in Idiopathic pulmonary fibrosis focuses on Nintedanib in particular. His work in Nintedanib tackles topics such as Pirfenidone which are related to areas like Gastroenterology, Symptomatic relief, Dermatology and Progressive disease.
His Severe acute respiratory syndrome coronavirus 2 study in the realm of Coronavirus disease 2019 interacts with subjects such as 2019-20 coronavirus outbreak. His Pandemic research incorporates elements of Global health and Severity of illness. The study incorporates disciplines such as Placebo, Tolerability and Idiopathic interstitial pneumonia in addition to FEV1/FVC ratio.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management
Ganesh Raghu;Harold R. Collard;Jim J. Egan;Fernando J. Martinez.
American Journal of Respiratory and Critical Care Medicine (2011)
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi;Roland M. du Bois;Ganesh Raghu;Arata Azuma.
The New England Journal of Medicine (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis;Ulrich Costabel;David M. Hansell;Talmadge E. King.
American Journal of Respiratory and Critical Care Medicine (2013)
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu;Martine Remy-Jardin;Jeffrey L. Myers;Luca Richeldi.
American Journal of Respiratory and Critical Care Medicine (2018)
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi;Ulrich Costabel;Moises Selman;Dong Soon Kim.
The New England Journal of Medicine (2011)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu;Bram Rochwerg;Yuan Zhang;Carlos A. Cuello Garcia.
American Journal of Respiratory and Critical Care Medicine (2015)
The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society
Geoffrey D. Rubin;Christopher J. Ryerson;Linda B. Haramati;Nicola Sverzellati.
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study
Giovanni Ferrara;Monica Losi;Roberto D'Amico;Pietro Roversi.
The Lancet (2006)
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard Hr;Ryerson Cj;Corte Tj;Jenkins G.
American Journal of Respiratory and Critical Care Medicine (2016)
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
Aryeh Fischer;Katerina M. Antoniou;Kevin K. Brown;Jacques Cadranel.
European Respiratory Journal (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: